Sphingosine kinase inhibitors
| dc.contributor.assignee | Virginia Tech Intellectual Properties, Inc. | en |
| dc.contributor.assignee | University of Virginia Patent Foundation | en |
| dc.contributor.department | Chemistry | en |
| dc.contributor.inventor | Lynch, Kevin R. | en |
| dc.contributor.inventor | Santos, Webster L. | en |
| dc.date.accessed | 2019-02-15 | en |
| dc.date.accessioned | 2019-02-26T22:24:05Z | en |
| dc.date.available | 2019-02-26T22:24:05Z | en |
| dc.date.filed | 2015-09-30 | en |
| dc.date.issued | 2018-10-16 | en |
| dc.description.abstract | Sphingosine kinases are enzymes that catalyze the biosynthesis of sphingosine-1-phosphate. The invention provides compounds that are effective for inhibition of sphingosine kinase type 1, sphingosine kinase type 2, or both. Certain compounds are selective for sphingosine kinase type 2 relative to sphingosine kinase type 1. Compounds of the invention can be used in treatment of a range of diseases wherein increasing the level of sphingosine-1-phosphate in blood is medically indicated. Diseases that can be treated by administration of an effective dose of a compound of the invention include a neoplastic disease that involves excess vascular growth; macular degeneration or diabetic retinopathy; an allergic disease such as asthma, an inflammatory disease of the eye such as uveitis, scleritis, or vitritis; an inflammatory disease of the kidney; a fibrotic disease; atherosclerosis; or pulmonary arterial hypertension. A compound of the invention can be used to improve the integrity of a vascular barrier in a disease where the vascular barrier is disrupted, such as cancer or Alzheimer's disease. | en |
| dc.format.mimetype | application/pdf | en |
| dc.identifier.applicationnumber | 15516333 | en |
| dc.identifier.patentnumber | 10100022 | en |
| dc.identifier.uri | http://hdl.handle.net/10919/87851 | en |
| dc.identifier.url | http://pimg-fpiw.uspto.gov/fdd/22/000/101/0.pdf | en |
| dc.language.iso | en_US | en |
| dc.publisher | United States Patent and Trademark Office | en |
| dc.rights | In Copyright | en |
| dc.rights.uri | http://rightsstatements.org/vocab/InC/1.0/ | en |
| dc.subject.cpc | A61K31/03 | en |
| dc.subject.cpc | A61K31/42 | en |
| dc.subject.cpc | C07D271/06 | en |
| dc.subject.cpc | C07C279/16 | en |
| dc.subject.cpc | C07D249/08 | en |
| dc.subject.cpc | C07D285/12 | en |
| dc.subject.cpc | C07D413/04 | en |
| dc.subject.cpc | C07D413/14 | en |
| dc.subject.cpc | C07D417/04 | en |
| dc.title | Sphingosine kinase inhibitors | en |
| dc.type | Patent | en |
| dc.type.dcmitype | Text | en |
| dc.type.patenttype | utility | en |
Files
Original bundle
1 - 1 of 1